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ULCERS IN RBSTRAIM RATS
STUDY OF PROTECTIVE SUBSTANCES
L. Duche and D. Gallaire
Pharmacology Institute
The pathogenesis of gastric ulceration in restrained rats is
still not understood. We do know f however, that there is an in-
fluence in the production of tbeoa lesions from the vagal nervous
system (9P lO t 11 9 12 9 1 3, 45, 46) and from factors originating in the
central system (9v 3-0 9 479 40-
Having at our disposal Ix technique described in previous publi-
cations (15, 18) inducing gastric ulcerations after immobilization dur-
ing a short period, has made it possible to determine the protective
action of various substances which have pharmacologic; effects during
the entire restraining period. We have used substanoes capable of
either peripheral parasympatholytic, sympatholytic, ganglioplegict
spasmolytic effects, or centralg hypnoticp tranquilizingg neurolep-
tic t analgesic effects.
Hoping to provide additional information relating-to the genesis
of ulcers in restrained ratso we have attempted to determine a rela-
tionship between the protective effects of all substances examined
vls-a*'-v:Ls ulcers in restrained rats and their elective or secondary
pharmacologic effects.
SUBSTANCES USED AND TECHNIQUES
I, Substances
The substances examined are capable of an elective effect on
either the peripheral or central nervous system,
li	 Substances with peripheral effects include:
1. Four parasympatholytics: three ester-amines, atropine sulfate,
dihexyverine or cycichexyl-l-cyclohexyl-carboxylate of piperidoethanol
*Numbers in the margin indicate pagination in the foreign text.
(Spasmodex*) and J , L. 1344 or phenyl-1-cyclohexyl-carboxyiate of pi-
peridinothanol in the form of chlorhydrates, a quartenary ammonium,	 i
benzylonium bromide, bromides bromide benzyl ,^c ester of N-diethyl-l-
hydroxypyrolidinium-3 (Portyn*).
2. Two sympatholytics: one acting mainly on the alpha receptors,
dibenamine, N, N O dibenzyl--;i• -chlorethylamine, in the chlorhydrete
form in a pH 2 solution, the other acting as an inhibitor of the l^,
receptore, propranolol, sopropylamino -1 (x naphthyloxy)-3 propanol-2,
in the chlorhydrate form (Inderal*).
3. One gangl ioplegics pentamathonium, dibromide of pentamethy-
lone-di- ( trimetbylammonium).
4. One papaverinic spasmolytic: papaverine hydrochloride.
Substances with central effects include:
1. Six hypnotics: one aldehyde, chloral hydrate; one urethane,
ethylurethane; four batbiturics: butobarbital (Soneryl *); tetrabarbi-
tal (Batysedal*), sodic pentaobarbital or mebubarbital (Nembutal*),
phenobarbital ( Gardenol*). Butobarbital, tetrabarbital and phenobar-
bital are solubi ,lized in the presence of sodium carbonate.
2. Two tranquilizers; carbamate of methyl -3-pentynol-3, (N-Obli-
von*) and meprobamate, proca .lmadio.l, dicarbamate of methyl-2-propyl-2
propane-diol-1-3 (Equanil*).
3. Six neurolepticss chlorpromazine, chloro 3-(dinmethylamino -31-
(propyl) -10-phenothiazine ( Largactil*), in the chlorhydrate form; reser-
pine in the pure crystallized alkaloids forme ( Serpasil*), in a so1u-
tion with a solvent having the following composition: citric acid,
2.5 mg, polyethylene glycol 300, 100 mg; distilled water q.s.p, l ml;
four derivatives of butyrophenonev haloperidol, R.162 5 9 41—fluoro
4(4 1 —chloro) -phenyl-piperidino))-butyrophenone (base); triperidol,
R.2498, 4 1 -fluoro-4-4-hydroxy-4-( 3 1 —trifluoromethyl-phenyl) -piperidine-
butyrophenone ( chlorhydrate); benperidol, R.4584 9	- -(4fluoro-
benzoyl) -propyl) -i-oxo-4-phonyl-2e 4, 8-trazaspiro- ( 4,5)-decane
1	 2
(chlorhydrate).
4. One analgesics dextromaoramide (Palfium)* in the bitartrate
form.
11, Technique	 L=
The technique used to produce gastric ulcerations in restrained
rats has been previously described (15, 18). Animals which under-
went a 24 hour hydratod fasting beforehand are immobilized for two
and one half hours at an ambient temperature of 21 + 4°C.
We experiment on female rats of Wstar stocky with a weight vary-
ing from 100 to 130 g; always taken from the same breeding.
The substances under examination are administered intraperitoneal-
lye usually fifteen minutes after the beginning of immobilization.
The hypnotics are injected fifteen minutes before restraining the
rate which makes it possible to avoid using ether anaesthesia to im-
mobilize the animals. More exceptionally t we have used intravenous
or oral routes. The volume administered varies from 0.25 to 0,50
ml/100 g of weight. Experiments are performed most often on groups
of at least twenty rats, The same day the rats are treatedv a group
of control rats are administered a physiological solution.
Changes in the percentage of animals developing ulcerations
and the average index, which accounts for the severity of the less-
ions t are calculated relative to the control animals and their sta-
tistical meaning is determined according to the process descrrbed
by FAVERGE (25).
RESULTS AND REMARKS
a^. Substances With Peripheral Effects
1. Parasympatholytics
The four parasympatholytics examinedg administered intraperi
	 {
toneally, exert various degrees of protective action vis-a-vis
_3
the ulceration in restrained rate; the average ulceration index varies
as a function of the decline in the percentage of rate stricken with
ulcerations (fig. 1). They may be classed by order of decreasing pro-
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index; g-Number of rats
Figure 1 - Action of parasympatholytic substances in the production
of ulcerations in restrained rats, which are administered
intraperitoneally, Significant results
are marked by an asterisk ( P less than 0.01).
tective action as follows; atropine sulfate ( *) greater than benzylon-
ium bromide greater than dihexyverine greater than J, L, 1344, since their
equiactive doses are 1.25 mg/Lgs 2.50 mg/kg, 50 mg/kg and more than
75 mg/kg.
We thought it would be of interest to compare these results with
the anticholinergic effects of these substances, determined on the iso-
lated duodenum of the rat by the Jeannne LEVY and SIOU.(42) technique
and their mydriatic effects in the rat following intraperitoneal ad-
ministration.
*Atropine sulfate is about 40 times more active than dihexyverine
through the oral route and through the intraperitoneal route.
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On the isolated organp the hierarchy of antichol.inergic effects 41
(27) is comparable to that established from the protection via-h-vis
the ulceration in restrained rata. This is also the case for the my-
driatic effects determined in vivo; let us note in addition that atro-
pine sulfate (0.5 mg/kg)v benzylonitun bromide (1.25/kg) and dihexy-
verine (10 mg/kg) are mydriatic at doses below those required to block
the production of ulcerations in restrained rats.
2. S_ympatholytics
Dibenamine t which inhibits the alpha-receptors when injected in-
traperitoneal.lypin one minute with a dose of 20 mg/kg (27% of DL50)t
exerts a certain degree of protection vis-a-vis ulceration in restrain-
ed rats (:fig. 2). we have verified that this dose administered to an
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Key: a-Percentage of rats showing ulcerations; b-Control rats;
c-Pentan►ethonium dibromide; d-Papaverine hydrochloride; e-Average
index; f-Number of rats T; g-Percentage of rats showing ulcera-
tions; h-average index # standard deviation.
Figure 2 - Action on the production of ulcerations in restrained rata
of dibenamine t propranololp pentamethonium dbromide and
papaverine hydrochloride administered intraperitoneally.
Significant results are marked with an asterisk (P less
than 0.01).
anaesthetized and atropined rat in the same conditions reduces the
hypertensive effects of adrenaline by 506 for a period of more
5
50;x, for a period of more than 60 minutes t after a latent time of 20
to 30 minutes. A dose of 10 mg/kg does not modify the adrenaline
effects.
Let us recall that dibenamine has central stimulating properties:
	 42
doses of about 35 tug/kg administered intravenously into the
mouse induces convulsions (44); it creates agitationp trembling and
interaggressivity in the rat and a state of hyperexcitability in
the mouse (28)0
Propranolol t
 which inhibits the receptors, does not reduce
the frequency of ulcerations (fig. 2) 9
 
even with a dose of 25 mg/lcgt
representing 33% of the DL50
 (determined by intraperitoneal injection
practiced in one minute). In the anaesthetized rat, 10 and 25 mg/lcg
of propranolol eliminates the hypotensive effects of isoprenaline in
10 minutesq whereas the hypertensive effects of adrenaline are po-
tentialized.
This substance is capable of central depressive and anticonvulsive
properties in the rat and the mouse at doses ranging between 5 and 40
mg/lcg administered subeutaneous3m- (40).
3. Ganglioplegic
Pentamothonium dibromide substantially reduces the percentage
of animals with ulcerations and the average index with a dose of 7,5
rng/lcg; the intensity of this protective action increases with a dose of
10 rng1kg (fig, 2). 'With the same dose and same ►neaps of administrations
we have found an extended gangliopl,egic in the anaesthetized and atro-
pined rat: hypertension induced by intravenous injection of phenoxy-
choline iodide (115 - :Ag k,,), excito-ganglionic (44) is fought for more
than 80 minutes.
Lot us recall that BRODIL and VALITSKI (14) use a test which as-
sociates coldness with restraining in the rat to prevent by adminis-
tering mecamylamine (Inversine*), the appearance of digestive hemor-
rhaging which occurs in the absence of this ganglioplegic. ANICH-
KOV and `LAVODSKAYA (2) bring to light the protective action
6
of hexamethonium vis-h-vis gastric ulcerations of reflex origin .n-
duced by applying clamps on the rat's duodenum.
4. Papaverinic Spasmolvtic
At doses varying from 5 to 20 mg/kg, papaverine hydrochloride
does not influence the production of ulcerations (fig. 2). According
to the MAOHT and RARBA-DOSE technique (43), it does not slow down the
intestinal tract in the rate even with a dose of 30 mg/kg (50% of DL 30)0
B. Substances With Central, Effects=
1. Hypnotics
Mebubarbital has been experimented by BONSFILS and associates
(10) 0 HANSON and BRODIE (29) 9 SIMLER and SCHWARTZ (49) 9 who use a re-
straining of 24 hours. The first authors find a moderate reduction in
tha percentage of ulcerations after administering a barbiturate at the
beginning of the restraining period. SIMLER and SCHWARTZ (49) show
that rats are protected for more than 24 hours when treated one day
prior to the restraining with a mebubaebital dose inducing a sleep of
5 to 6 hours.
On figure 3, we have summarized the results relating to the fre- L142
quency of ulcerations and the average index after administering six.
hypnotics (*) and combinations of chloral hydrate-butobarbital#
urethanoobutobarbital (16). We have shown on the same figure tho
sleeping period induced by the doses used. We have used inactive or
efficient liminar doses inducing an experimental sleep of 10 to 15
minutes together with strong doses, whether fractioned or not, indu-
cing a sleeping period just as long or longer than the restraining
periods i.e. 150 minutes t With these latter dosesp it has been ob-
served that a mortality of 5 to 200 is characteristic with most hyp-
notics (16)0
At efficient liminar or inactive dosesp phenobarbital. (60 mg/kgg
or 60% hypnotic liminar dose) is the only active hypnotic; it reduces
*It has been administered intraperitoneallyp except for one pheno-
barbital dose of 140 mg/kg injected intravenously.
7
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Significant results are marked with an asterisk (P less than 0.01).
First part: with nonhypnotic or efficient liminary doses.
Second part: with doses inducing a sleeping period equal to or
longer than the restraining period.
Third part: by combining.
Figure 3 - Action of hypnotic substances on the production of ulcer-
ations in restrained rats,
the percentage of animals with ulcerations and the average index (fig.
3, first part). Let us recall that phenobarbital has important anti-
convulsive properties, especially in the rat sensibilized by nico-
tinylhydrazideg where it fights acoustic epilepsy with a dose of 10
mg/kg administered intraperitoneally (19). Moreover, tetrabarbital,
which is ineffective vis-a-vis ulcerations in restrained rats with
a nonhypnotic dose of 12.5 mg/kg, fights acoustic epilepsy with a
dose of 2.5 mg.kg (19).
t I
When the experimental sleep laste throughout the restraining
period # all of the substances used exert a protective action # except
for the special case of urethane. The intsnsit-^- of the protective
action depends on the type of hypnotic used * harbitury*k s are much
more active than chloral hydrate; they are placed by order of do-
creasing activity as follows phenobarbital greater than mebubarbi-
tal greater than totrabarbital greater than butobarbital greater than
chloral hydrate (fig, )i part 2). Whereas barbiturates decrease the
percentage of animals striken with ulcerations a,lor?g with the average
index # this is not the case with chloral hydrate. The only signifi-
cant result of this latter substance relates to the number of animals
protected. Moreover # these results may be compared with those ob-
tained by ANICHKOV and ZAVODSKAXA (2)s vie -h-vis the gastric ulcera-
tion of reflex origin induced in the rat by applyin G a clamp on the
duodenums the phenobarbital exerts a preventive action # whereas chloral
hydrate has no effect.
A combination of the inactive doses of chloral hydrate and buto
barbital (fig. 3; part 3) causes the sice ping period to last through-
out the restraining period # due to the effect of potentialization # and
exerts a considerable protective action (percentage of animals rrotee-
ted and average index).
The case of urethane must be distinguished from that of other hyp-
notics, In fai.L. urethane # which is nonulcerogenic with a dose of
700 mg/kg # becomes ulcerogenic with a dose of 1 9 400 mg/kg. In this
case # it causes gastric ulcerations in 42% of the animals which are
not restrained. For restrained rats # on the other hand # the ulcero-
genic effects of urethane are not combined with the restraining effects.
The number of animals with ulcerations is reduced to 48% 9 which is
very close to the results with the same dose of urethane for non-
immobilized animals, Accordingly # it is possible to .distinguish the
ulcerogen c effects of urethane from its protective action via -h-vis
the ulceration of restrained rats. On the other hand # by combining
a nonulcerogenic dose of urethane (700 mg/kg) with butorbarbital # the
number of animals with ulcerations decreases by 11% with an average
index of 0.3 (fig. 3 #
 part 3).
9
2, Tranquilizers
With a benactyzIne dose of 24 mg/kg, HANSON and BRODIE obtain a
considerable protectior in rats restrained for four hours after a 48
hour fasting, ANICMOV and GRECHISKIN (1) show there is an inhibiting
action exerted by benactyzine on the gastric secretion induced by ace-
tyloholine l since the two substances are injected by intracarotid
route.
According to HAOT and associates (30) ► a dose of 50 mg/kg of	 46
chlordiazepoxide permits a 50% reduction in the percentage of ulcer-
ations caused by a 5 to 6 hour restraining,
In experiments made with meprobamate (procalmadiol) and methyl-
pontynol carbamateg a 250 mg/kg dose of meprobamate ensures a cer-
tain degree of protection (fig, 40, Even a 250 mg/kg dose of meth-
ylpentynol, which induces a. state close to sleep during the restrain-
ing periodo does not exert a significant protective action (fig. 4 )0
Let us point out that a 35 mg/kg dose of meprobamate and meth-
ylpentynol administered intraperitonenllyv exerts Fa protective action
vis-h-vis the acoustic epilepsy in rats sensitized with nicotinyl-
hydrazide (19).
3. Neuroleptics
Reserpine, capable of ulcerogenic properties by itself (17t 380n
39 0 53) t does not exert a protective action via-h-vis ulcers in re-
strained rats; it canp howeverp increase the frequency of ulcers (79
17 t 21), Chlorpromazine has been experimented with doses varying
between 5 and 20 mg/kg by FONTAN and associates (26) 9 HANSON and
BRODIE (29), BONSFILS and associates (8) t BUCHEL and GALLAIRE (15, 1'1)
Authors are unanimous to state that it has a protective action in rats
restrained for 2 1/2 to 24 hours. The other derivatives of phenothia-
zine (th ioridazine (8), methopromazine (26), thioproperazine (8.3))
decrease the frequency of ulcers in rats restrained for seven hours.
When the animals are restrained for 24 hours, thioproperazine has no
effects even if it is repeatedly administered during the restraint.
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Figure It - Lffects of two tranquilizers and one analgesic on the ;pro-
duction of ulcers in restrained rats. Si6nifIcant results
are marked with an asterisk (P lass t1lan 0.01).
Lavomepromazine and acepromazine (26) do not exert a preventive action
and even seem to increase the frequency of ulcers.
The cataleptogenic doze of chlorpromazine administered intraperi-
toneally varies from 3.3 mg/kg to 16 mglkg (5)9 depending on the test
used, From these resultap doses of chlorpromazine (5 to 20 mg/kg),
which wore shown to be protective via-a -via ulcers in restrained rats
in our experiments (17), may be considered as ca:ta.leptogenic. Further•
morep doses of 2 and 5 mg/kg of chlorpromazinev administered intra.peri-
toneally in the rat e exert sedative effectsp since they potential.ize
the experimental sleeping periods induced by chloral hydrate and hexo-
barbital (20), respectively.
We have examined four derivatives of butyrophononev which were
synthesized and studied by JAN5EEN and his associates (32w 33t 369 39) 9
for their action on the production of ulcers in restrained rate in
11
l
•	 x
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comparison with reserpino and chlorpromazine. They are haloperidol#
triperidoly benzperidol and spiroperidol with donee from 0.1 to 10
mg/kg (17). These substances have cataleptogenic properties ( 36, 51).
We hwve thus verified that a 0.1 mg/kg dose of benzperidol adminis- 	 1^.
tered intraperitoneally, induces a moderate catalepsy one hour after
the inj ection and that a 0.1 mg/kg dose of all of these substances
creates cataleptic states after 30 and 60 minutesp which 'become ex-
cessive between the first and second hour.
None of these derivatives everts an ulcerogenic action with the
strongest doses used t whereas it is produced in 100% of the animals
with the cataleptogenic dose of 5 mg/kg of resperine (17).
We may summarize as follows the results obtained for the preven-
tive action via-a-vis ulcers in restrained rats. Doses of 0.2 to
5 mg/kg of haloperidol reduces neither the frequency nor the severity
of the ulcers; with a dose of 10 mg/kg, which is highly catalepto-
geniep we observe a moderate decrease (60% Instead of 81%) t which is
insignificant ( 0.01 less than p less than 0 . 05) in the percentage of
ulcerated stomachs t w, •Zhout a modification in the average index.. A
similar action is observed for a 0.2 mg/kg dose of triperidolp whereas
the administration of 1 to 5 mg does not produce a preventive action.
A 0.1 mglkg dose of benzperidoly which is already cataleptogenic # does
not significantly modify the frequency of ulcers; it does # howevery
decrease the average ?ndex. A 1 mg/kg dose is without effect. A
0.2 mg/kg dose of spiroperidol reduces moderatel,yt but significantlyg
the percentage of animals with ulcers; there is no protective action
when the dose rises to 1 mg/kg.
None of the four butyrophenone derivatives exerts a regular and
important protective actions regardless of the doses used: small doses
slightly depress the motility of the animalsp especially at the be-
ginning of the restraining; strong doses create a cataleptic state.
Under the same experimental conditionsp we confirm both the protec-
tive acton of chlorpromazine, the intensity of which is a function of
the dose used (5 to 20 mg/kg) and the aggravating action of reserpine
( 1.5 to 2.5 mg/kg).
12
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4 * Analgesic
SULM And associates (50) have brought to light the inhibiting
ration of morphine via-&-vi* the frequency of ulcers in rats restrained
for 24 hours.
We have used dextromoramido (16) ► An analgesic which has been
synthesized and studied by JANSSEN And JAGNAV (34 t 35). The calcula-
ted donee have varied from 0e25 to 2 mg/kg,
Doxt.-oworamido oxerts an important protective action (percentage
of nnimals protected and average index) vie-h-vis ulcers of restrained
rata t
 with a dose of 0.5 mg/kg. In the tests we have used, it is
,,neither nnnlgostioo nor oatelptogeniop nor mydriatiep but block* the
intestinal tract in the rat.
With the hoazing plate of WOOLFE wid MACDONALD (52)9 which was 	 1548
modified by JACOB and BLOZOVSXI (31)p we have obtained analgesia only
with a I Ing/kg close (*) administered Intrnporitonesi.11y; this Action
is characteristic in 70% of the rats paid is effective on the average
60 minutes * With the anme dome, 30% of the rats show a slight rigi-
dityo whereas the dose of 2 mg/kg described by CHARPENTIER (22) and
studied by DOISSIVR and associates (6) ► produces a catnloptic state
which Insts more than 150 minutes, A I mg/kg dose of aoxtromoramide
creates a mydriasisp wbiob is effective for 45 minutes.
A O._5 mg/kg dose of dextromornmide f which is neither analgesic
nor mydrinticv slows clown the intestinal tract, since the importance
of its action Is e qual to that inducod by 1,03 mg/kg of base atropine.
This is comptirable to the results which JAN 1 5SEN nnd JAGENAU (34) ot-
served in the mouse (luring the investigation of the intestinal tract 
the action of doxtromornmido is stronger thim that of atropine sulfate,
the doses of which :ire respectively 3.72 z,incl 16.5 mg/kg. We may ask
*According to JANSSEN and JAGENAU ()5) 0 the dextromoramide dose ad-
ministered subcutaneouslyg which causes anal igesa in. 50% of the rats 
is 0.38 mg/kg with the heating plate test.
13
ourselves If the delay In the •ilitestftett) tract ituty be attributed to
the miti.chol-InarKi c properties o;V tioxtromornmi do.
Given tbese experimetntnl datup it seemed interesting to compare
the pnpaveerinic tind titre] pink notions of dextromornmitle ill vl tro. A
ooncontrat:ion in the Isolated rat duode nun! cif 1.$7 x tO -6 desxtrouiora-
mide reduces	 controct-ions by 509b. This notion
is much stronger than the petpaverinic, affect of atropIno sulfatepr
which shows ctn effect on]y for concentrations of 1100 to 500 X 1060
Since Fl t>:pttsneogextic action of rtcetyl- -ee ►etilyl ehol-lne bromide urith the
stuue intens lty as tblit induced, by barium chloral de Is blocked by the
sinus concentrntion of dextromommide (1.87 X 10 6 )r It :is not possible
to attribute nn atrop In i c spitsmolyt,i c tecti:011 ill vitro (27) to deextro-
mornmide.
DrSCUSSTON
;i:. Sub5tnnge5 Witt! Pe33r'i.ojerail. FXfacts
.A. constant Lind Important protection vis -h-v:i s the u.l.cer in re-
strained rats is obtained with all substanoes capn.U1_.ri of antalchol i-
ner gi c proport°i.es exerted tYt the peripheral level (tt,trol);txlo su1 fate,
bouz.1.1onl.um bromidee t e• ihoxyver,i.nee e J.L. 11 14-4) or at the gnugl;i.on;.i.c
synapse ;level, ( pontnmathonium) . 1!'ven though this tact i oii accurs t for
parnsymptitholytics tit doses 2 to 5 times h i ghor thnil thoso i h l ob ill-
duce mydri sis i_n the rtit t its intensity is on to par with the degree
of ontiebolinergic ttction. Moreover, we have checked that spasmo'lytIc.
pt>pavicer.i1110 w:ithou.t otrop:ine proportlos door 'not ilffect the ul.certlti oxi. r40
A snuill protection wtis obtained only with o sympietholYtic acting
,It the level of the : ndrenergic receptorse dibenam3.ne. `.l`he ntQClytl-
nism of this protection remwl!!s undetermined even. if we tissuute tout
di bennm:ine has the centritt stimulating properties described by corta i n
authors (;z8, 44).
Cn summ tryo oll of those results confirm the .importtunce of the
vag,a,l norvous factor in the genclsi s of i TCQrs In restrained rats.
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X1, Substances With Central Effects
Among the central depressi-e substances which we have examinedp
phenobarbital and dextromoramide have proven to be quite effective
via-h-vis ulcers in restrained rats,
Phenobarbital reduces the frequent, of alcers at a dose which is
not yet hypnoticp contrary to other barb`t,xrzc derivativesp mwbubarbi-
tall tetrabarbi.talp outobarbital and chloral hydratep which are effec-
tive only when they induce narcosis during the restraining period. As
for urethanes which is ulcerogenic in the unrestrained anirnal t
 its
protective action prevails when it is used at a dose which extends the
sleep in the immobilized animal.
It is not very likely that the protective action of phenobarbital
may be attributed to a peripheral anticholinergic effects which we
have not been able to illustrate on the isolated duodenum of the rat.
It also does not seem that the anticonvulsive properties of barbi-
turates may play a major role in the protective action of phenobarbi-
tal. The anti.convulsive actions of phenobarbital and tetrabarbital
are similar in their different antiulceration effects. Accordi.nglyt
phenobarbital reduces the frequency of ulcers at a dose which is six
times stronger than the anticonvulsi.ve dose and 2 times weaker than
the hypnotic dose. Tetrabarbi.tal is ineffective at a. dose which is
five times stronger than the anticonvulsi.ve dose.
Analgesic dextromora.mide is considered an an,tiebolinergic by
some authors (22, 34) . It combats the production of ulcers in re-
strained rats with a dose which is neither analgesic nor mydriatic in
the ra.ty but which slows clown the intestinal tract. Even though anti-
cholinergic properties of dQ.tromoramide b ve not been demonstrated
on the isolated duodenum of the rat, it is not excluded that central
anticholinergic effects slow clown. the intestinal tract and have a
protective action vis-h-vis ulcers in restrained rats.
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Among the neuroleptics tested, only chlorpormazine reduces
without el;im:im-tang the production of ulcers in restroined rids; der-
ivatives of butyrophenone do not significantly Influence the frequency
of ulcers, wl erons reserpine is ul.coxogenic. Moreover, at the closes
used, all of these substances exert a ca.tal.eptogenlc action; accordingly,
the latter sloes not seem to play .a, determining role in antiulcerous
effects.
For the two tranquilizers exnmi.nedp even at doses much higher tha,r-
the sedr-.five doses, no observation was made of ca preventive action with
methyl-pentynol carbmitnte and ca small, degree of protection is obtained
with proc-almaadiol.
In summary, the pharmacological renctives which we have used have
not made it possible to define the .levels at whielr r; Central factor
is exerted in the antiulcerous effects of phonobarbit.il, doxtromormide
;rnd chlorpormazine.
CONCLUSIONS
The antiulcerous action of substances electively exerting peripher-
al or central effects is determined in restrained rats.
1. The regular and considerable protection observed with para-
sympatholytics (atropine sulfate, benzylonium bromide, dihexyverine,
J.L. 13 1 4) and a ganglioplei;ic (pentametboniurrr) is a function of their
anti Clio linergic properties. It is of less :importance with dibennmine,
a sym. ^atholytic Faction on the
	 mirenergi..c receptors.
2. Among the central depressive substances tested. (hypnotics,
tranquilisers, neurol,epties, anol.ges:ic), phonobarbital at a nonhypnotic
close, and dextromor-im iAe of n nonanalgesic close, show antiulcerous
effects, which are found with chlorpromazine only at cot;aleptogenic
doses,
3. The m e cbmr nism of intiulcerous effects is discussed.
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